Treatment of Nodular Basal Cell Carcinoma (BCC) With Imiquimod 5% Cream After Curettage
This study has been completed.
Information provided by:
Wake Forest School of Medicine
First received: April 12, 2006
Last updated: NA
Last verified: March 2005
History: No changes posted
To assess the efficacy of treating a nodular basal cell carcinoma with imiquimod cream after initial treatment with curettage
Basal Cell Carcinoma
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
||Topical Imiquimod 5% Cream in the Treatment of Nodular Basal Cell Carcinoma After Initial Treatment With Curettage
Primary Outcome Measures:
- histologic clearance of basal cell carcinoma
| Estimated Enrollment:
| Study Start Date:
| Estimated Study Completion Date:
The primary objective of this study is to evaluate the efficacy of imiquimod 5% cream on nodular BCC lesions treated 5x/week for 6 weeks after primary treatment with curettage without electrodesiccation. The secondary objective of this study is to evaluate the cosmetic outcome after treatment of the lesions using this modality.
|Ages Eligible for Study:
||18 Years and older
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
- Are willing and able to give informed consent;
- Are at least 18 years of age;
- Are willing to comply with all study requirements, evaluations, and procedures
Have 1 clinically typical, visible nodular BCC lesion which meets the following criteria:
- a primary lesion (not recurrent, not previously treated or biopsied)
- size between 0.25 and 1.5 cm2
- located at least 1 cm from the eyes, nose, mouth, ear, and hairline to exclude the H-zone of the face
- clinically consistent with nodular BCC
- histologically consistent with nodular BCC and have no histological evidence of a morpheaform or micronodular pattern
- suitable for treatment with surgical excision
- easily identifiable and treatable by subject or reliable subject representative
- Are free of any significant physical abnormalities or previous scarring in the potential application site area that may cause difficulty with examinations.
- Are willing to stop using over-the-counter retinol products or products containing alpha or beta hydroxyacids in the treatment and surrounding area 8 hours prior to treatment with the imiquimod cream and clinic visits.
- Have evidence of clinically significant, unstable, cardiovascular or immunosuppressive, hematologic, hepatic, neurologic, renal, endocrine, collagen-vascular, or gastrointestinal abnormalities or disease that may interfere with completion of the study.
- Have any dermatological disease in the treatment or surrounding area that may be exacerbated by treatment with imiquimod or cause difficulty with examination.
- Have a BCC lesion located within 1 cm of the eyes, nose, mouth, ear, and hairline.
- Are pregnant at the screening or treatment initiation visit.
- Have known allergies to any excipient in the study cream
- Have undergone any surgical procedures in the potential treatment area within 4 weeks of the screening/treatment initiation visit. In addition, skin in the potential application area must be healed.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00314756
|Wake Forest University Medical Center
|Winston-Salem, North Carolina, United States, 27157 |
Wake Forest University
||Phillip M Williford, MD
||Wake Forest University Medical Center
No publications provided
History of Changes
|Other Study ID Numbers:
|Study First Received:
||April 12, 2006
||April 12, 2006
||United States: Institutional Review Board
Keywords provided by Wake Forest School of Medicine:
nodular basal cell carcinoma
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on October 13, 2015
Carcinoma, Basal Cell
Neoplasms by Histologic Type
Neoplasms, Basal Cell
Neoplasms, Glandular and Epithelial
Physiological Effects of Drugs